Chugai Pharmaceutical (OTCMKTS:CHGCY) Upgraded at Smbc Nikko Sec.

Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical (OTCMKTS:CHGCY) to a strong-buy rating in a research report released on Wednesday morning,Zacks.com reports.

Separately, UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

OTCMKTS CHGCY opened at $33.61 on Wednesday. The business’s 50 day moving average price is $28.29 and its 200-day moving average price is $25.41. Chugai Pharmaceutical has a fifty-two week low of $19.50 and a fifty-two week high of $34.84. The company has a market cap of $110.61 billion, a P/E ratio of 38.63 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.25 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. The business had revenue of $2.25 billion for the quarter. As a group, equities analysts predict that Chugai Pharmaceutical will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.